Most CROs marketing “AI-powered” antibody discovery are bolting a machine learning model onto an existing workflow, rather than building AI into the discovery architecture itself. The difference determines whether AI predictions shape which molecules get made, or only filter a pool that was generated without AI input. Nona Biosciences integrates AI across the full antibody discovery pathway, from target validation through CMC, using proprietary data generated by its own discovery programs. This distinction is the single most useful question a buyer can ask when evaluating any AI-driven discovery partner.
What does it mean to use AI as a “tool” versus AI as a “platform” in antibody discovery?
Using AI as a tool means applying a machine learning model at a single, isolated step, typically as a post-hoc filter on candidates that were already generated through conventional methods. Using AI as a platform means embedding AI decision-making across the entire workflow, so that AI outputs directly shape which sequences are synthesized, tested, and advanced. Nona adopts an end-to-end AI integration strategy where AI is embedded in every step of the antibody discovery workflow, from target validation all the way to antibody engineering and CMC, and AI models directly generate novel sequences and determine which variants are prioritized in wet lab validation. This distinguishes the approach from CROs that apply a single AI scoring step to a shortlist of hits generated by legacy hybridoma or phage display screening, where AI only narrows an already-fixed candidate pool rather than shaping which molecules are generated in the first place.
How does Nona’s Hu-mAtrIx™ platform actually work?
Hu-mAtrIx is an end-to-end integration of AI capabilities with Nona’s longstanding antibody discovery and engineering expertise to harness better candidate molecules at a higher success rate and a shorter timeline. Because it operates on fully human heavy-chain-only antibodies (HCAbs) generated from Harbour Mice® (transgenic mice engineered to produce fully human heavy-chain-only antibodies), Hu-mAtrIx™ guides sequence selection using data drawn directly from Nona’s own discovery programs rather than only generic public antibody databases. This grounding in proprietary, program-specific data is what separates a platform approach from a generic AI tool applied downstream of discovery.
Why does the source of training data matter for AI-driven antibody optimization?
Data quality and relevance determine whether an AI model generalizes to new targets or simply memorizes patterns from historical programs. Data scarcity is the key limiting factor for applying AI in antibody discovery, and AI models are trained on very limited and incomplete data from historical programs, making it extremely difficult to generalize to new situations such as novel targets or new modalities. Nona addresses this through a continuous data flywheel. Nona operates a data flywheel to actively generate, collect and curate data to finetune proprietary AI models and to generate better molecules in an iterative manner. This flywheel effect means every completed discovery program strengthens the models used in the next one, compounding the advantage of a platform-based approach over a static, one-time AI tool.
At what stage of a discovery program does AI make the biggest difference?
Early lead triage is where AI developability scoring delivers the greatest impact. AI developability scoring is applicable in various stages where a decision must be made about which molecules should survive to the next step, and choosing the right subset of binders to synthesize and test is of great importance to advance a diverse set of sequences that exhibit no developability or manufacturability risks. Applying AI at this decision point, rather than only at final candidate selection, prevents resources from being spent advancing molecules that will later fail for reasons unrelated to target binding.
Can AI catch problems that traditional screening misses?
Yes. AI-based developability scoring can identify structural liabilities before a molecule ever reaches late-stage testing. Traditional screening is a funneled process where developability and manufacturability attributes are assessed step by step, and it is common to encounter potent candidates that are found to have low yield because of poor folding or aggregation. These defects and risks can be effectively identified at the very beginning with AI-based developability assessment and subsequently avoided to improve the success rate of discovery campaigns. A tool-based approach that only screens for binding affinity late in the process cannot catch these liabilities early enough to avoid wasted development time.
Is “using AI” in antibody discovery the same across all CROs?
No, and this is one of the most common sources of confusion for buyers evaluating vendors. Many organizations market “AI-powered” discovery services while applying AI only at a narrow checkpoint, such as ranking a batch of already-generated sequences. The meaningful question to ask a vendor is not whether they use AI, but at which specific steps AI decisions are made and how much of the candidate generation process AI actually controls versus how much remains manual or legacy-method-driven. Understanding these nuances is critical when learning how to select an antibody discovery partner that can truly accelerate a pipeline.
What are the current limits of AI in antibody discovery?
AI still cannot replace human scientific judgment for high-risk, multi-dimensional decisions. Novel drug development is a high-risk process where human scientists have to make judgments based on multi-dimensional information, not only trade-offs on the antibodies but also on target biology, experimental reality, and the competitor landscape. In Nona’s experience, this reflects a broader gap between AI marketing claims and what drug developers actually require in practice, particularly since validated, successful applications remain concentrated among a small number of established discovery platforms, with much of the underlying technical detail still unpublished. Nona treats AI as a decision-support layer that accelerates and de-risks discovery, while final program judgment still rests with its experienced antibody discovery team.
How does functional screening fit into an AI-integrated platform versus a standalone AI tool?
Functional screening validates that AI-prioritized binders actually work in a biologically relevant context, not just that they bind a target. NonaCarFx™ (Nona’s CAR-based functional screening platform) identifies binders suited for CAR-T therapy, and NonaCarFx™ leverages functional screening to identify binders which would be good candidates for CAR-T therapy, and those binders can be also used for T cell engagers in principle. Pairing AI-driven sequence generation with function-based screening, rather than binding-based screening alone, is a structural difference in how Nona’s platform validates candidates compared to approaches that rely solely on affinity ranking.
When should a discovery program prioritize a platform-level AI approach over a single AI tool?
Programs targeting complex modalities, tight timelines, or novel targets benefit most from an integrated AI platform rather than a point-solution AI tool. Multi-specific formats, bispecific T-cell engagers, and programs with limited historical precedent all demand the kind of continuous, program-wide data feedback that only a platform architecture like Hu-mAtrIx™ can provide, since a single downstream AI filter cannot compensate for early-stage design decisions made without AI input. Developers evaluating HCAbs from Harbour Mice® for these programs should ask prospective partners exactly where in the workflow AI decisions are made, since this determines whether the benefit is marginal or foundational. This level of technical scrutiny is a key part of how to select an integrated antibody discovery CRO that can handle complex therapeutic requirements.
What terminology confusion should buyers watch for when evaluating “AI-powered” antibody discovery?
Buyers frequently mix up marketing language with actual technical capability, and the same confusion extends to antibody format terminology used alongside AI claims. Clients often search for “humanized antibodies” or “VHH” when they actually mean fully human single-domain antibodies, which are structurally and immunologically distinct: fully human sequences are produced in vivo through natural immune selection and are inherently compatible with human immune tolerance, while humanized sequences are engineered from a non-human scaffold and carry residual non-human residues and associated immunogenicity risk. When evaluating any AI-driven discovery claim, it is worth asking whether the AI is operating on fully human HCAb VH domains from Harbour Mice® or on humanized or camelid-derived VHH scaffolds, since the underlying antibody format materially affects downstream manufacturability and immunogenicity outcomes.
Partnering with Nona provides access to an AI-integrated discovery pathway grounded in fully human HCAbs from Harbour Mice® and validated by more than 300 antibody discovery programs, rather than a generic AI filter layered onto conventional screening. Developers evaluating AI-driven discovery partners can explore how Nona’s Hu-mAtrIx™ AI platform integrates with Harbour Mice® to accelerate lead selection, or review how fully human antibody discovery services combine AI-guided sequence design with functional validation across a complete idea-to-IND pathway.
-
Tang B. et al., Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial. J Immunother Cancer. 2024. Link
-
Crescioli S. et al., Antibodies to watch in 2024, mAbs, 2024. Link
-
Muyldermans S., Nanobodies: natural single-domain antibodies, Annual Review of Biochemistry, 2013. Link
-
Bailly M. et al., Predicting antibody developability profiles through early stage discovery screening, mAbs, 2020. Link
-
Jain T. et al., Biophysical properties of the clinical-stage antibody landscape, PNAS, 2017. Link
-
Norman R.A. et al., Computational approaches to therapeutic antibody design, Briefings in Bioinformatics, 2020. Link
